CYTK plans FDA submission for aficamten in non-obstructive HCM
CYTK says aficamten showed robust efficacy and manageable safety in non-obstructive HCM, with an FDA submission planned.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.